Chroma Medicine Announces Appointment of Jenny Marlowe, Ph.D., as Chief Development Officer
Ohio Pen/10262764

BOSTON, May 20, 2024 ~ Chroma Medicine, Inc. has recently announced the appointment of Jenny Marlowe, Ph.D., as their new Chief Development Officer. Dr. Marlowe brings with her a wealth of experience and expertise in the field of genomic medicine, making her a valuable addition to the company's leadership team.

According to Catherine Stehman-Breen, M.D., CEO of Chroma, the company is thrilled to have Dr. Marlowe on board during this crucial time as they prepare to transition to clinical trials. Her leadership and knowledge will be instrumental in bringing their innovative epigenetic editing therapies to patients.

Prior to joining Chroma, Dr. Marlowe served as the Chief Scientific Officer at Solid Biosciences (previously AvantiBio), where she led discovery, research, and translational development. She also held the position of Vice President of Preclinical and Translational Development at bluebird bio, where she played a key role in the development of Zynteglo, a gene therapy for beta thalassemia that has since been approved.

More on Ohio Pen
Dr. Marlowe's career began at Novartis, where she held various leadership positions including Global Head of Strategic Planning and Communication and Director of Translational Safety Models in Preclinical Safety. She holds a Ph.D. in Molecular Toxicology from the University of Cincinnati and a B.S. in Zoology from Miami University.

In her new role at Chroma, Dr. Marlowe will be focusing on advancing their epigenetic editing platform which utilizes the cell's natural system to regulate gene expression without altering DNA. This technology has shown great potential for creating groundbreaking medicines.

Expressing her excitement about joining Chroma, Dr. Marlowe stated that their epigenetic editing platform is an incredibly compelling technology for developing transformative medicines. She is eager to work with the team at Chroma and help bring this new class of genomic therapies to patients.

With Dr. Marlowe's extensive experience and expertise, Chroma is well-positioned to continue their pioneering work in the field of genomic medicine and bring hope to patients in need of innovative treatments.
Filed Under: Business

Show All News | Report Violation


Latest on Ohio Pen